Sep 7, 2022 05:52 PM
(This post was last modified: Sep 7, 2022 06:28 PM by C C.)
Cancers in adults under 50 on the rise globally
https://www.sciencedaily.com/releases/20...161454.htm
SUMMARY: A study reveals that the incidence of early onset cancers (those diagnosed before age 50), including cancers of the breast, colon, esophagus, kidney, liver, and pancreas among others, has dramatically increased around the world, with this drastic rise beginning around 1990. In an effort to understand why many more younger individuals are being diagnosed with cancer, scientists conducted extensive analyses of available data in the literature and online, including information on early life exposures that might have contributed to this trend.
Study shows “living drug” can provide a lasting cure for cancer
https://leaps.org/car-t-cell-therapy/particle-1
INTRO (excerpts): Doug Olson was 49 when he was diagnosed with chronic lymphocytic leukemia, a blood cancer that strikes 21,000 Americans annually. [...] Olson, a scientist who developed blood-testing instruments, knew the odds...
[...] Soon afterward, however, his doctor revealed a possible escape route. ... The experimental treatment, known as CAR-T therapy, would use genetic engineering to turn his T lymphocytes (immune cells that guard against viruses and other pathogens) into a weapon against cancer.
In September 2010, technicians took some of Olson’s T cells to a laboratory, where they were programmed with new molecular marching orders and coaxed to multiply into an army of millions. When they were ready, a nurse inserted a catheter into his neck. At the turn of a valve, his soldiers returned home, ready to do battle.
Three weeks later, Olson was slammed with a 102-degree fever, nausea, and chills. The treatment had triggered two dangerous complications: cytokine release syndrome, in which immune chemicals inflame the patient’s tissues, and tumor lysis syndrome, in which toxins from dying cancer cells overwhelm the kidneys. But the crisis passed quickly, and the CAR-T cells fought on. A month after the infusion, the doctor delivered astounding news: “We can’t find any cancer in your body.”
“I felt like I’d won the lottery,” Olson says. But he was only the second person in the world to receive this “living drug,” as the University of Pennsylvania investigators called it. No one knew how long his remission would last.
An Unexpected Cure. In February 2022, the same cancer researchers reported a remarkable milestone: the trial’s first two patients had survived for more than a decade. Although Olson’s predecessor—a retired corrections officer named Bill Ludwig—died of COVID-19 complications in early 2021, both men had remained cancer-free. And the modified immune cells continued to patrol their territory, ready to kill suspected tumor cells the moment they arose.
“We can now conclude that CAR-T cells can actually cure patients with leukemia,” University of Pennsylvania immunologist Carl June, who spearheaded the development of the technique, told reporters. “We thought the cells would be gone in a month or two. The fact that they’ve survived 10 years is a major surprise.” (MORE - missing details)
https://www.sciencedaily.com/releases/20...161454.htm
SUMMARY: A study reveals that the incidence of early onset cancers (those diagnosed before age 50), including cancers of the breast, colon, esophagus, kidney, liver, and pancreas among others, has dramatically increased around the world, with this drastic rise beginning around 1990. In an effort to understand why many more younger individuals are being diagnosed with cancer, scientists conducted extensive analyses of available data in the literature and online, including information on early life exposures that might have contributed to this trend.
Study shows “living drug” can provide a lasting cure for cancer
https://leaps.org/car-t-cell-therapy/particle-1
INTRO (excerpts): Doug Olson was 49 when he was diagnosed with chronic lymphocytic leukemia, a blood cancer that strikes 21,000 Americans annually. [...] Olson, a scientist who developed blood-testing instruments, knew the odds...
[...] Soon afterward, however, his doctor revealed a possible escape route. ... The experimental treatment, known as CAR-T therapy, would use genetic engineering to turn his T lymphocytes (immune cells that guard against viruses and other pathogens) into a weapon against cancer.
In September 2010, technicians took some of Olson’s T cells to a laboratory, where they were programmed with new molecular marching orders and coaxed to multiply into an army of millions. When they were ready, a nurse inserted a catheter into his neck. At the turn of a valve, his soldiers returned home, ready to do battle.
Three weeks later, Olson was slammed with a 102-degree fever, nausea, and chills. The treatment had triggered two dangerous complications: cytokine release syndrome, in which immune chemicals inflame the patient’s tissues, and tumor lysis syndrome, in which toxins from dying cancer cells overwhelm the kidneys. But the crisis passed quickly, and the CAR-T cells fought on. A month after the infusion, the doctor delivered astounding news: “We can’t find any cancer in your body.”
“I felt like I’d won the lottery,” Olson says. But he was only the second person in the world to receive this “living drug,” as the University of Pennsylvania investigators called it. No one knew how long his remission would last.
An Unexpected Cure. In February 2022, the same cancer researchers reported a remarkable milestone: the trial’s first two patients had survived for more than a decade. Although Olson’s predecessor—a retired corrections officer named Bill Ludwig—died of COVID-19 complications in early 2021, both men had remained cancer-free. And the modified immune cells continued to patrol their territory, ready to kill suspected tumor cells the moment they arose.
“We can now conclude that CAR-T cells can actually cure patients with leukemia,” University of Pennsylvania immunologist Carl June, who spearheaded the development of the technique, told reporters. “We thought the cells would be gone in a month or two. The fact that they’ve survived 10 years is a major surprise.” (MORE - missing details)
